Catch up on the latest global health technology assessment (HTA) news and browse our past issues.
HTA Quarterly Archive
In this issue, our editors examine ICER's approach to Unsupported Price Increase (UPI) assessments, how health disparities play a pivotal role in health outcomes of marginalized patient populations, and how the evolution of cancer therapeutics offers opportunities to gain insights from key opinion leaders in oncology.
In this issue, our editors examine two new tools from the Institute for Clinical and Economic Review (ICER), assess the value of vaccines from an HTA perspective, and provide an update from our previously published infectious disease economic model on the COVID-19 pandemic.
In this issue, our editors examine how real-world evidence impacts regulatory decisions in the United States, the current state of reimbursement for Advanced Therapy Medicinal Products (ATMPs) in Germany, and a look at two value assessment frameworks Innovation and Value Initiative (IVI) and the Institute for Clinical and Economic Review (ICER).
In this issue, our editors examine ICER's growing influence payer decisions making, subscription-based antibiotic programs, and the path into the German healthcare market for advanced therapy medicinal products.
In this issue, our editors examine market access in South Korea, new treatments for Alzheimer's disease, new policies in China, and the patient role in ICER value assessments.
In this issue, our editors examine digital health technology (DHT) from a global perspective, the value drivers for emerging gene therapies for hemophilia, and the impact of the European Union’s new medical devices guidance on DHTs.
In this issue, our editors examine the patient voice and HTA, updates to the ICER and NICE frameworks, and the changing healthcare landscape in India with the adoption of their own HTA.
In this issue, our editors examine cost-effectiveness assessments for innovative but high-cost treatments, market access for cell and gene therapies in key European countries, and newest joint HTA assessments, FINOSE.
In this issue, we review HTA frameworks for next-gen sequencing in precision oncology, how HTAs review tumor-agnostic therapies, and the rise of complex technologies and their reimbursement landscape. Read our special feature, Hot Topic, on the changes in France’s healthcare system on medicinal products.
In this issue, we examine the impact of the 21st Century Cures Act on stakeholders in the United States, explore the proposed rule from the Centers for Medicare & Medicaid Services on managed care value-based formulary decisions, and consider how patient input can help influence drug development.
In this issue, we take a closer look at the utilization of “multiple criteria decision analysis” (MCDA) in health technology appraisals, newer therapies for Cystic Fibrosis, and the regulatory pathways and complexity of health technology assessment (HTA) evidentiary hurdles for new diabetes drugs, devices, and combination technologies.
We examine wearable technology and big data, valuing CAR-T therapies, and a look at Catalonia and the region's autonomous healthcare market.
Late Summer 2018
We examine the world's second largest pharmaceuticals market as Japan shifts from a traditional reimbursement assessment. We look at new therapies for Tardive Dyskinesea. We also review Taiwan's Center for Drug Evaluation on its 10 year anniversary.
We take a look at whether value frameworks are the path to implementing value-based pricing, the EMA's move out of the United Kingdom, and look at the health policy trends in Canada from InnomarLive.
We examine oncology appraisal differences between NICE and SMC, market access for cell and gene therapies, and managed entry agreements.
Late Summer 2017
We examine medical nutrition reimbursement, severe asthma therapies, and brazil's healthcare market.
We take a look at patient input into HTA decisions in 4 countries, examining new therapies for Duchenne Muscular Dystrophy, and understanding the Colombian universal healthcare model.
We examine the process to appeal unfavorable NICE decisions, provide insights on immunotherapy coverage and reimbursement, and take a deeper look at global value dossiers.
We examine indication-specific pricing in Europe and in the US, approved therapies for multiple myeloma, and take a closer look at Portugal's HTA body, SiNATS.
We examine rapid access in the US, UK, and France, targeted therapies for psoriasis and psoriatic arthritis, and explore Singapore's highly efficient healthcare system.